United States Patent and Trademark Office - Sales Receipt -

04/06/2006 RHARMON 00000001 501050 10764373

01 FC:1814 130.00 DA

Adjustment date: 08/10/2006 SDIRETA1 04/06/2006 RHARMON 00000001 501050 10764373 01 FC:1814 130.00 CR



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Arnold S. Lippa; Joseph W. Epstein

Title:

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0] Hexane,

Compositions Thereof, and Uses As A Dopamine

Reuptake Inhibitor

Serial No.:

10/764,373

Filing Date:

January 23, 2004

Atty. Dk. No.:

DOVP-1-0604

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited in the United States Postal Service as First Class mail in an envelope addressed to: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450, on this 30th day of June, 2006.

Susan M. Wanger

REQUEST FOR REFUND OF EXCESS PAYMENT (37 CFR 1.28)

TO THE COMMISSIONER FOR PATENTS:

The undersigned, as attorney of record for the inventors identified above, with respect to the instant patent application, hereby requests that applicants' Deposit Account charge of \$130.00 (Fee Code 1814) for submission of a Terminal Disclaimer, filed on April 4, 2006, be refunded pursuant to 37 CFR 1.28. The correct amount of the charge should have been \$65.00.

The applicant qualifies as a small business concern as defined in 13 CFR § 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. The applicant was erroneously charged large entity fees. A copy of the Deposit Account Statement listing the charges is also enclosed.

Please issue an immediate credit/refund in the amount of \$65.00 to Deposit Account 50-1050.

Should there be any question concerning this Request, a call to the undersigned attorney is encouraged.

DATED this 30th day of June, 2006.

Respectfully submitted,

BLACK LOWE & GRAHAM PLLC

Jeffrey J. King, Esq.

Registration No. 38,515

Attorneys for Applicant

701 Fifth Avenue - Suite 4800

Seattle, WA 98104

Telephone: (206) 381-3300

Facsimile: (206) 381-3301



UNITED STATES PATENT AND TRADEMARK QUITCE

JUE 0 3 5000 %

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

MONTHLY STATEMENT OF DEPOSIT ACCOUNT

To replenish your deposit account, detach and return top portion with your check. Make check payable to Director of Patents & Trademarks.

BLACK LOWE & GRAHAM PLLC 701 5TH AVENUE, SUITE 4800 SEATTLE WA 98104 FINA

Account No.								
, 501050								
Date								
	4-28-06							
Page								
	<u> </u>							

PLEASE SEND REMITTANCES TO: U. S. Patent and Trademark Office P.O. Box 70541 Chicago, IL 60673

DATE POSTED CONTROL		CONTROL	DESCRIPTION		 	FEE	CHARGES/		
MO.	DA	Y YR.	NO.	(Serial, Patent, TM, Order)	DOCKET NO		CODE	CREDITS	BALANCE
4	3		30	PCT/US06/08436	DOV	/P-11-1904	1703	1500.0	0 1185.00
4	3		31	PCT/US06/08436	DOVP-11-1904		1702	1086.0	99.00
4	3		32	PCT/US06/08436	DOVP-11-1904		8007	20.0	
4	5		76	E-REPLENISHMENT			9203	-6000.00	0 6079.00
4	6		1	10764373	2370-006-07		1814	130.00	5949.00
4	6		2	10764371	DKT03139		1814	130.00	5819.00
4	6	1	2	11290639	WYET-1-0101		1081	500.00	5319.00
4	6		4	11290639	WY	ET-1-0101	1202	100.00	5219.00
4	6		31	11290639		ET-1-0101	1202	500.00	4719.00
4	7	06	1	10480322	34009	0.402USPC	1251	120.00	4599.00
4	7	06	1	10878960	-		2202	125.00	4474.00
4	7		2	10878960			2201	200.00	4274.00
4	7	06	29	5815843			9204	-300.00	4574.00
4	-	06	100	29251296			9204	-40.00	4614.00
4		06	9	PCT/USO6/03408			9204	-145.00	4759.00
4		06	24	11367532			9204	-650.00	5409.00
4	11	06	221	11399840	SMAR-1-1101		2111	100.00	5309.00
4		06	223	11399840	SMAR-1-1101		2311	100.00	5209.00
4	11	06	224	11399840	SMAR-1-1101		2202	650.00	
4		06	225	11399840	SMAR-1-1101		2201	700.00	
4		06	1	10785383	INJS-1-1003		2202	75.00	
4		06	2	10785383	INJS-1-1003		2201	600.00	3184.00
4		06	70	11229339	2469-001-03		2202	50.00	3134.00
4			32	11254242	DOVP-1-2001		2011	150.00	
4	13	06	33	11254242	DOVP-1-2001		2111	250.00	2734.00
4	13	06	34	11254242	DOVP-1-2001		2311	100.00	2634.00
4	13	06	35	11254242	DOVP-1-2001		2051	65.00	
	13	06	36	11254242	DOVP-1-2001		2252	225.00	2344.00
	24	06	. 8	09884854	WING-1-1016		2201	100.00	2244.00
		06	186	PCT/US05/39220	ONLN-11-1001		8007	20.00	
		06	2	10068106	1		9204	-250.00	2474.00
4	27	06	30	10301999	BOE	BOE1-1-1101		1370.00	1104.00
							1453		
<u>ا</u>				SUFFICIENT TO	OPENING BALANCE	TOTAL CHAI	RGES	TOTAL CREDITS	CLOSING BALANCE
COVER ALL SERVICES REQUESTED MUST ALWAYS BE ON DEPOSIT					2685.00	8966.0	0	7385.00	1104.00

MS020C (11/2005)

*** O.D. INDICATES OVERDRAWN



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

2006 JUL -7 FN 3: 42

Arnold S. Lippa; Joseph W. Epstein

US PATENT & TRADEMARK

OFFICE

Title:

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0] Hexane,

Compositions Thereof, and Uses As A Dopamine

Reuptake Inhibitor

Serial No.:

10/764,373

Filing Date:

January 23, 2004

Atty. Dk. No.:

DOVP-1-0604

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited in the United States Postal Service as First Class mail in an envelope addressed to: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450, on this 30th day of June, 2006.

Susan M. Wunger(

Enclosures:

Request For Refund of Excess Payment (37 CFR 1.28)

Copy of Deposit Account No. 50-1050 (04/06/06)

Postcard

.

PTO/S8/25 (10-05)

Approved for use through 07/31/2008. OMB 0551-0031-U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING

Docket Number (Optional)

REJECTION OVER A PENDING "REFERENCE" APPLICATION DOVP-1-0804 (2370-006-07) in re Application of: Amold S. Lippa; Joseph W. Epstein Application No.: 10/764,373 Filed: January 23, 2004 For. (-)-1-(3.4-Dichlorophenyl)-3-Azabicyclo[3.1.0] Hexane, Compositions Thereof, And Uses As A Dopsmine-Reuptake Inhibitor The owner, <u>DOV PHARMACEUTICAL INC.</u> of <u>100</u> percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number <u>10/764,371</u> filed on <u>Isourary 23, 2004</u>. as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on eald reference replication may be shortened by any terminal disablest filed and the first and a filed to the statut of the statut application hereby disclaims, except the provided by the statut of the statut application for the statut application hereby disclaims, except the statut application hereby disc on _tanuary 23, 2004 _____, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the ewner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that any such patent; granted on the pending reference application: expires for failure to pay a maintenance fee, is held unemforceable, is found invalid by a court of compatent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 97 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate. For submissions on bahalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that withth false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or egent of record. Reg. No. 38.515 April 4, 2006 Signature Typed or printed name (206) 381-3300 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. WARNING: Information on this form may become public. Credit card information ehould not be included on this form. Provide credit card information and authorization on PTO-2038. "Statement under \$7 CFR 3.73(b) is required if terminal disclaimer is signed by the assignes (owner).

Statement under 57 CPR 3.73(p) is required it remains executive to segree by the assignment (owner). Form PTO/SB/98 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CPR 1.321. The information is required to obtain or rotain a banefit by the public which is to tile (and by the USPTO to process) an application. Confidentising the completed by 35 U.S.C. 122 and 37 CPR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gastering, preparing, and submitting the completed application forms to the USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or auggestations for reducing the burden, should be serve to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need sealstance in completing the form, cell 1-809-PTQ-9199 and select option 2.

PAGE 315 * RCVD AT 4/4/2006 3:08:01 PM [Eastern Daylight Time] * SVR:USPTO/EFXRF-319 * DNIS:2730709 * CSID:2063813301 * DURATION (mm-ss):03-26

8